This article is more than 5 years old. Information may no longer be current.
Nikkiso acquires Baxter's continuous renal replacement therapy business
Click Here to Manage Email Alerts
Nikkiso America, Inc. announced it has completed the acquisition of Baxter International Inc.'s legacy Continuous Renal Replacement Therapy (CRRT) business. CRRT is a therapy used primarily for patients in the ICU in need of blood purification due to acute kidney injury or fluid overload. Nikkiso has been the original equipment manufacturer of the Aquarius CRRT System for Baxter and is extending its presence in the acute renal failure marketplace. The newly acquired global acute renal therapy business will be run out of Nikkiso America, which operates the company's medical, aerospace, and industrial divisions in the United States.
(Baxter wins European approval for new home hemodialysis machine)
Under the terms of the transaction, Nikkiso acquired Baxter's legacy CRRT portfolio, including its acute renal therapy product line: the Aquarius System, Aqualine and Aquaset tubing sets, Aquamax hemofilters and Accusol solution. The acquisition also includes the transfer of proprietary Baxter ClearFlex CRRT pharmaceutical solution manufacturing technology and equipment, marketing and distribution rights, intellectual property, and associated agreements. Approximately 85 employees around the world supporting the CRRT business will transfer to Nikkiso, subject to local laws. Final financial terms of the transaction are not being disclosed.
"Nikkiso is a pioneer in blood purification products. For more than half a century, Nikkiso has addressed the needs of caregivers while focusing on improving treatment outcomes for the patients who use these therapies," said Thomas Kelly, president of Global CRRT Nikkiso America.